Integrin-mediated regulation of hematopoiesis: Do bcr/abl-lnduced defects in integrin function underlie the abnormal circulation and proliferation of cml progenitors?

Acta Haematologica

Volumn 97, Issue 1-2, 1997, Pages 40-52

  Verfaillie, Catherine M ^a   Hurley, Randy ^a   Lundell, Beverly I ^a   Zhao, Chunhua ^a   Bhatia, Ravi ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adhesion; Chronic myelogenous leukemia; Integrins; Intracellular signaling; P210 tyrosine kinase; Proliferation

Indexed keywords

BCR ABL PROTEIN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; FIBRONECTIN; INTEGRIN; ONCOPROTEIN;

BONE MARROW CELL; CELL ADHESION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL;

BONE MARROW; CELL ADHESION; CELL DIVISION; CONNECTIVE TISSUE; EXTRACELLULAR MATRIX; FIBRONECTINS; FUSION PROTEINS, BCR-ABL; HEMATOPOIESIS; HUMANS; INTEGRINS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TUMOR STEM CELLS;

EID: 15444344198     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203658     Document Type: Article

References (148)

1. Dexter TM. Coulinho I.H, Spooncer E. Hey-worth CM. Daniel CP. Schiro R. Chang J. Allen TD: Stromal cells in haemopoiesis: Molecular control of haemopoiesis. Ciba Found Symp 1990;148:76-95.
2. Verfaillie CM. Hurley R. Bhatia R. McCarthy JB Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol He-matol 1994:16:201-224.
3. Chabannon C, Torok-Storb B: Stem cell-slro-mal cell interactions. Curr Top Microbiol Immunol 1992;177:123-135.
4. Kincade PW: Cell interaction molecules and cytokines which participate in B lymphopoiesis. Ballierc’sClin Haematol 1992:5:575-598.
5. Whitlock CA. Witte ON: Long-term culture of B lymphocytes and their precursors from murine bone marrow. Proc Natl Acad Sci USA 1982;79:3608-3611.
6. Miller JS. Verfaillie CM. McGlavc PB: The generation of natural killer cells from CD34+ HLA-DR- primitive progenitors in human long term bone marrow culture. Blood 1992; 80:2182-2187.
7. Allen TD. Dexter TM: Long-term bone marrow cultures: An ultrastructural review. Scan Electron Microsp 1983:4:185 - 1866.
8. Lichtman MD: The relationship of stromal cells to hemopoietic cells in marrow: in Wright DG, Greenberger JS (eds): Long-Term Bone Marrow Culture. Liss, New York. 1984, pp 57-96.
9. Coloumbel L. Eaves AC. Eaves CJ: Enzymatic treatment of long-term marrow cultures reveals the preferential location of primitive hematopoietic progenitors in the adherent layer. Blood 1983:62:291-299.
10. Dexter TM. Coutinho LH. Spooncer E: Stroma cells in haemopoiesis. Ciba Found Symp 1990: 48:76-95.
11. Weiss RE, Reddi AH: Apperance offibronectin during the differentiation of cartilage, bone and bone marrow. J Cell Biol 1981;88:630-636.
12. Gordon MY: Extracellular matrix of the marrow microenvironment. Br J Haematol 1988; 70:1-4.
13. Toskoz D. Zsebo KM. Smith KA. Hu S. Brano-kow D. Suggs SV, Martin FH. Williams DA: Support of murine hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane bound and secreted forms of the human homologue of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 1993:89:7350-7354.
14. Caldwell J. Palsson BO, Loccy B. Emerson SG: Culture perfusion schedules influence the metabolic activity and growth factor production rates of human bone marrow stromal cells. J Cell Physiol 1991:147:344-353.
15. Burrhoughs JM, Gupta P. Verfaillie Soluble factors from the mouse fibroblast cell line M210-B4 support in vitro hematopoiesis. Exp Hematol 1994:22:1095-1101.
16. Gordon MY. Riley GP. Watt SM, Greaves MF: Compartmentalization of a haematopoietic growth factor GM-CSFj by glycosaminogly-cans in the bone marrow microenvironment. Nature 1987:326:403-405.
17. Gordon MY. Riley GP. Watt SM, Greaves MF: Stem cell factor induction of in vitro murine hematopoietic colony formation by ‘subliminal' ctokine combinations: The role of'anchor' factors. Blood 1992:80:663-669.
18. Yoder MC, Williams DA: Matrix molecule interactions with hematopoietic stem cells. Exp Hematol 1995:23:961-967.
19. Shofield R: The relationship between the spleen colony-forming cell and the hematopoietic stem cell: A hypothesis. Blood Cells 1978:4:7-25.
20. Siczkowski M. Clarke D. Gordon MY: Binding of primitive hematopoietic progenitor cells to marrow stromal cells involves heparan sulfate. Blood 1992:80:912-919.
21. Long MW. Dixit VM: Thrombospondin functions as a cytoadhesion molecule for human hematopoietic progenitor cells. Blood 1990,75: 2311-2318.
22. Long MW. Briddcll R. Walter AW. Bruno E. Hoffman R: Human hematopoietic stem cell adherence to cytokines and matrix molecules. J Clin Invest 1992;90:251-255.
23. Campbell AD. Long MW. Wicha MS: Hemo-nectin. a bone marrow adhesion protein specific for cells of granulocytic lineage. Nature 1987;329:744-747.
24. Gordon MY. Dowdling CR. Riley GP. Goldman JM. Greaves MF: Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1984:328:342-344.
25. Verfaillie CM. McCarthy JB. McGlave PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibroncctin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992:90:1232- 1241.
26. Bhatia R. Wayner E. McGlave P. Verfaillie CM: Interfcron-u restores adhesion of malignant progenitors in CML by restoring pi inte-grin function. J Clin Invest 1994;94:384-391.
27. Bhatia R. Wayner E. McGlave P. Verfaillie CM: Interfcron-u restores adhesion of malignant progenitors in CML by restoring pi inte-grin function. J Clin Invest 1995:96:931 -939.
28. Lundcll Bl.McCarthy JB. Kovach NL, Verfaillie CM: Adhesion to fibronectin (FN) induced by the activating anti-integrin-pl antibody, 8A2. restores adhesion mediated inhibition of CML progenitor proliferation. Blood 1996: in press.
29. Hurley RW, McCarthy JB. Verfaillie CM: Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 1995:96: 511-519.
30. Verfaillie C. Blakolmer K, McGlave P: Purified primitive hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Med 1990:172:509-520.
31. Simmons PJ, Masinovsky B. Longenccker BM, Bcrerson R. Torok-Storb B. Gallatin WM: Vascular cell adhesion molecular-! expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992:80:388-395.
32. Verfaillie CM. Benis A. lida G. McGlave PB. McCarthy J: Adhesion of committed human hematopoietic progenitors to synthetic peptides in the C-terminal heparin-binding domain of fibronectin: Cooperation between the integrin u4pl and the CD44 adhesion receptor. Blood 1994:84:1802-1812.
33. Verfaillie CM. McCarthy JB. McGlave PB: Differentiation of primitive human multipo-tent hematopoietic progenitors into single lineage clonogcnic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 1991;174:693-703.
34. Wayner EA. Garcia-Pardo A. Humphries MJ. McDonald JA, Carter WG: Identification and characterization of the T lymphocyte receptor for an alternative cell attachment domain [CS-I] in plasma fibrinogen. J Cell Biol 1989:109: 1321-1330.
35. Guan JL. Hynes RO: Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor a4pl. Cell 1990:60: 53-61.
36. McCarthy JB, Skubitz APN. Zhao Q. Yi X, Mickelson DJ. Klein DJ. Furcht LT: RGD-independent cell adhesion to the carboxy-tcr-minal heparin-binding domains of fibronectin involves heparin dependent and independent activities. J Cell Biol 1990:110:777-786.
37. hl stem cells to bone marrow stroma. J Clin Invest 1992:90:358-367.
38. Kerst JM, Sanders JB. Slaper-Cortenbach ICM. Doorakkers MC. Hooibrink B. van Oers RHJ. von dem Borne AEGK,: a4pl and a5pl are differentially expressed during myclopoicsis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way. Blood 1993:81: 344-351.
39. Ruoslahti E. Piersbacher MD: New perspectives in cell adhesion: RGD and integráis. Science 1987:238:491-497.
40. Pytela R. Piersbacher MD, Ruoslahti E: Identification and isolation of a 140 kD cell surface glycoprotein with properties expected of a fibroncctin receptor. Cell 1985:40:191-199.
41. Williams DA. Rios M. Stephens C. Patel VP: Fibronectin and VLA-4 in haematopoietic stem ccll-microcnvironment interactions. Nature 1991;352:438-441.
42. Papayannopoulou T. Craddock C. Nakamolo B, Priestley GV. Wolf SN: The VLA4/VCAM adhesion pathway defines contrasting mechanisms of lodging of transplanted murine hematopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995:92: 9647-9651.
43. Zanjani E. Papayannopoulou T: Human CD34+ cell transplanted in utero in sheep fetuses treated with anti-human VI.A4 remain ‘homeless’ and persist in circulation. Blood 1994;84(suppl 1): 1962a.
44. Papayannopoulou T, Nakamato B: Systemic treatment of primates with anli-VLA4 leads to an immediate egress of hemopoietic progenitors to peripherv. Proc Natl Acad Sci USA 1993:90:9374-9378.
45. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992:69: 11-12.
46. Singer JS: Intercellular communication and cellcell adhesion. Science 1992;255:1671-1677. Juliano RL, Haskili S: Signal transduction from the extracellular matrix. J Cell Biol 1993:120: 577-585.
47. Damsky CH. Werb Z: Signal transduction by integrin receptors for extracellular matrix: Cooperative processing of extracellular information. CurrOpin Cell Biol 1992:4:772-781.
48. Verfaillie CM: Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood 1992:79:2821- 2826.
49. Verfaillie CM: Soluble factor(s) produced by human bone marrow stroma increase cytokine induces proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 1993: 82:2045-2054.
50. Verfaillie CM. MIP-la combined with IL3 maintains primitive human LTBMC-IC for at least 8 weeks in ex vivo ‘stroma-noncontact’ cultures. J Exp Med 1994; 179:643-649.
51. Verfaillie CM. Miller JS: A novel single cell proliferation assay demonstrates that LTC-IC maintenance over time results from the extensive proliferation ofa small fraction of LTC-IC. Blood 1995:86:2137-2145.
52. Verfaillie CM, Catanzarro P: Development of a novel single LTC-IC proliferation assay that can determine the fate of LTC-IC over time. Leukemia, in press.
53. Broxmeyer HE, Sherry B, Lu L. Cooper S, Oh K-O, Tekamp-Olson P. Kwon BS. Cerami A: Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood 1990;76: 1110-1116.
54. Tanaka Y, Adams DH. Hunshcr S, Hirano H, Siebenlist U, Shaw S: T-ccll adhesion induced by proteoglycan immobilized cytokine MIP-15. Nature 1993;361:79-82.
55. Eaves CJ, Cashman JD, Kay RJ, Dogherty GJ, Otsuka T, Gaboury LA. Hogge DE. Landsdorp PM. Eaves AC. Humphries RK: Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent laver. Blood 1990:78:110-117.
56. Massague J. Chelfctz S, Boyd FT. Andres JL: TGF-p receptors and TGF-p binding proteoglycans: Recent progress in identifying their functional properties. Ann NY Acad Sci 1990; 593:59-72.
57. Albelda SM, Buck CA: Integrins and other cell adhesion molecules. FASEB J 1990:4:2868- 2880.
58. Hemlcr ME. Huang C. Schwarz L: The VLA protein family. J Biol Chem 1987:262:3300- 3309.
59. Pavalko FM, Otey CA: Role of the adhesion molecule cytoplasmatic domains in mediating interactions with the cytoskeleton. Proc Soc Exp Biol Med 1994:205:282.
60. Clark EA. Brugge JS: Integrins and signal transduction pathways: The road taken. Science 1995:268:233-239.
61. Miyamoto S, Akiyama SK, Yamada KM: Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science 1995:267:883-885.
62. Schaller MD. Otey CA. Hildebrand JD, Parsons JT: Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol 1995:130:1181 - 1187.
63. Komberg LT, Eaip HS. Turner CE. Prockop C. Juliano RL: Signal transduction by integrins: Increased protein tyrosine phosphorylation caused by clustering of p 1 integrins. Proc Natl Acad Sci USA 1992;157:105-132.
64. Guan J-L. Trevithick JE, Hynes RO: Fibronec-tin/integrin interaction induces tyrosine phosphorylation of a 120-kDa protein. Cell Rcgul 1991;2:951-964.
65. Burridge K, Turner CE. Romer LH: Tyrosine phosphorylation of paxillin and pi 25 FAK accompanies cell adhesion to extracellular matrix: A role in cytoskelctal assembly. J Cell Biol 1992;119:893-903.
66. Calalb MB. Poltc TR. Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: A role for Src family kinases. Mol Cell Biol 1995;15:954-963.
67. Beilis SL. Miller JT, Turner CE: Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase. J Biol Chem 1995:270:17437-17441.
68. Schaller MD, Parsons JT: ppl25FAK-depen-dcnt tyrosine phosphorylation of paxillin creates a high-affinity binding site for CrK. Mol Cell Biol 1995:15:2635-2645.
69. Kharbanda S, Saleem A, Yuan Z, Emoto Y, Prasad KV. Kufe D: Stimulation of human monocytes with macrophage colony-stimulating factor induces a Grb2-mcdiatcd association of the focal adhesion kinase ppl25FAK and dynamin. Proc Natl Acad Sci USA 1995:92: 6132-6136.
70. Chen HC, Guan JL: Association of focal adhesion kinase with its potential substrate phosphatidyl inositol 3-kinasc. Proc Natl Acad Sci USA 1994;91:10148-10152.
71. Chen HC, Guan JL: Stimulation of phosphati-dylinositol 3'-kinase association with focal adhesion kinase by platelet-derived growth factor. J Biol Chem 1994;269:31229-31233.
72. Teng KK, Lander H. Fajardo JE. Hanafusa H. Hempstead BL. Birgc RB: v-Crk modulation of growth factor-induced PCI2 cell differentiation involves the Src homology 2 domain of v-Crk and sustained activation of the Ras/mito-gen-activated protein kinase pathwav. J Biol Chem 1995:270:20677-20685.
73. Yurochko AD, Liu DY. Eierman D, Haskili S: Integrins as a primary signal transduction molecule regulating monocyte immediate-early gene induction. Proc Natl Acad Sci USA 1992: 89:9034-9038.
74. Brooks PC. Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T. Klier G, Cheresh DA: Intc-grin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994.79:1157-1164.
75. Davis LS. Oppenheimer-Marks N. Bednarczyk JL. McIntyre BW, Lipsky PE: Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol 1990: 145:785-793.
76. Dike LE, Farmer SE: Cell adhesion induces expression of growih-associated genes in suspension arrested fibroblasts. Proc Natl Acad Sci USA 1988:85:6792-6797.
77. Miyake K. Medina Kl., Hayashi S-l, Ono S. Hamoka T. Kincadc PW: Monoclonal antibodies to Pgp-1/C'D44 block lympho-hemo-poiesis in long-term bone marrow cultures. J Exp Med 1990;171:477-488.
78. Hurley RW. McCarthy JB. Wayner E. Vcrfail-lie CM: Monoclonal antibody induced clustering of the alpha 4 intcgrin inhibits hematopoietic progenitor proliferation. Exp Hematol 1994:22:335.
79. Fialkow PJ, Jacobson RJ. Papayannopoulou TH: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977:63:125-131.
80. Bakhshi A. Minowada J, Arnold A, Cossman J. Jensen JP. Whang-Peng J, Waldmann TA, Korsmeyer SJ: Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. N Engl J Med 1983;309:826-831.
81. Rowley JD: The Philadelphia chromosome translocation: A paradigm for understanding leukemia. Cancer 1990:65:2178.
82. Bartram CR. de Klein A. Hagemcijcr A. van Agthoven T. Gcurts van Kessel A, Bootsma D. Grosveld G. Ferguson-Smith MA, Davies T. Stone M: Translocation of the c-ahl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature 1983: 306:277-280.
83. Dhut S. Champlin T, Young BD: BCR-ABL and BCR proteins: Biochemical characterization and localization. Leukemia 1990:4:745-750.
84. Daley GQ. Van Ettcn RA. Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210^kr, al, l geneofthe Philadelphia chromosome. Science 1990:247:824-829.
85. Gishizky ML. Witte ON: Initiation of dysregu-lated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992:256:836-839.
86. Pendergast AM. Gishizky ML. Havlik MH, Witte ON: SHI domain autophosphorylation of p210 bcr/abl is required for transformation but not growth factor independence. Mol Cell Biol 1983:13:1728-1732.
87. Pendergast AM. Muller AJ. Havlik MH. Maru Y. W'itte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABI. SH2 regulatory domain in a nonphosphotyrosine-dcpcndent manner. Cell 1991:66:161-171.
88. Sawyers CL. McLaughlin J. Witte ON: Genetic requirement for RAS in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995:181:307-313.
89. Goga A. McLaughlin J. Afar DEH. Safiran DC. Witte ON: Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995:82:981-991.
90. Pendergast AM. Quilliam LA. Cripe LD, Bass-ing CH. Dai Z,: BCR-ABL-lnduccd oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993:75:175-185.
91. Gotoh A. Miyazawa K. Ohvashiki K. Tauchi T. Boswell HS. Broxmcycr HE. Toyama K: Tyrosine phosphorylation and activation of focal adhesion kinase (pl25FAK) by BCR-ABL oncoprotein. Exp Hematol 1995.
92. Salgia R. J. Salgiali J Biol Chcm 1995:270: 5039-5047.
93. Oda T. Heaney C. Hagopian JR. Okuda K. Griffin JD. Okuda K,: Crkl is the major tyrosinc-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-22928.
94. de Jong R. ten Hoeve J, Hcisterkam N, Grof-fcn J: Crkl is complexed with tyrosine-phos-phorylated Cbl in Ph-positive leukemia. J Biol Chem 1995;270:21468-21471.
95. Ilaria RL Jr. Van Etten RA: Constitutive activation of stat family members in BA/F3 cells transformed by P210 BCR/ABL. Blood 1995; 86(suppl):264.
96. Carlcsso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of stat proteins in hematopoietic cells transformed by p210 BCR/ABL. Blood 1995:86 (suppl):264.
97. Van Etten RA, Jackson PK, Baltimore D, Sanders MC. Matsudaira PT. Janmey PA: The COOH-terminus of the c-abl tyrosine kinase contains distinct F-actin and G-actin binding domains with bundling activity. J Cell Biol 1994:124:325-340.
98. Skorski T. Kanakaraj P. Nicborowska-Skors-ka M, Ratajczak MZ, Wen SC, Zon G, Ge-wirtz AM, Perussia B. Calabretta B: Phospha-tidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995:86:726-736.
99. Barnett MJ. Eaves CJ. Phillips GL. Gascoyne RD. Hogge DE. Horsman DE, Humphries RK. Klingemann HG. Lansdorp PM. Namel SH: Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study. Blood 1994;84:724-732.
100. Deisseroth AB. Zhifei Z, Claxton D, Hanania EG. Siquing F. Ellcrson D, Goldberg L. Thomas M. Janiceck K. Anderson WF, Hester J. Korbling M, Durelt A, Moen R. Bcrenson R. Heimfcld S, Hamer J, Calvert L, Tibbits P. Talpaz M. Kantarjian H, Champlin R. Reding C: Genetic marking shows that Ph+ cells present in autologous marrow of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplants in CML. Blood 1994:83:3068-3076.
101. Claxton D, Hanania EG. Siquing F. Ellcrson D, Goldberg L. Thomas M. Janiceck K. Anderson WF: Selective overshoot of Ph-negative blood hemopoietic cells after an intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Stem Cells 1993:1 67-71.
102. McGlave PB. Arthur D, Miller WJ. Lasky L, Kersey J: Autologous transplantation for CML using marrow treated ex vivi with recombinant human interferon gamma. Bone Marrow Transplant 1990;6:115-120.
103. Lccmhuis T. Leibowitz D. Cox G, Silver R. Srour EF, Tricot G. Hoffman R: Identification of BCR/ABL-negativc primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993:81:801-807.
104. Kirk JA, Reems JA. Roccklein BA. Van De-vanter DR. Bryant EM, Radieh J. Edmands S. Lee A, Torok-Storb B: Benign marrow progenitors are enriched in the CD34+/HLA-DRIo population but not the CD34+/ CD38!o population of chronic myeloid leukemia: An analysis using interphase fluorescence hybridization. Blood 1995:86:737-743.
105. Vcrlaillie CM. Miller WJ. Boylan K. McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of DR antigen expression. Blood 1992:79:1003-1010.
106. Spiers ASD: The clinical features of chronic granulocytic leukemia. Clin Hematol 1977:6: 77-95.
107. Kantarjian HM. Smith TL. McCredie KB. Keating MJ. Walters RS. Talpaz M. Hester JP. Bligham G. Gehan E. Frcireich EJ: Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985:66:1326-1335.
108. Eaves AC, Cashman JD. Gaboury LA, Kalou-sek DK. Eaves CJ: Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 1986: 83:5306-5310.
109. Bedi A, Zehnbauer BA. Barber JP. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994:83:2048-2058.
110. Smctscrs TFCM, Skorski T. van de Lochl LTF. Wcssels HM, Pennings AH, de Witte T, Calabretta B. Mcnsink EJ: Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BVI73. Leukemia 1994:8:129-140.
111. Shattil SJ. Hoxie JA. Cunningham M, Brass LF: Changes in the platelet membrane glycoprotein llb-IIla complex during platelet activation. J Biol Chem 1985:260:11107-11114.
112. Phillips DR. Charo IF, Scarborough RM: GPUb-IIfa: The repsonsive integrin. Cell 1991:65:359-362.
113. Sims PJ. Ginsberg MH, Plow EF, Shattil SJ: Effect of platelet activation on the conformation of the plasma membrane glycoprotein llb-IIla complex. J Biol Chem 1991:266: 7345-7352.
114. Collcr BS: Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986:103:451-456.
115. Kovach NL. Carlos TM. A monoclonal antibody to ßi integrin [CD29] stimulates VLA-dependcnt adherence of leukocytes to human umbilical vein endothelial cells and matrix components. J Cell Biol 1992:116:499-509.
116. Wayner EA, Kovach NL: Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J Cell Biol 1992:116:489-497.
117. Lozzio BB. Lozzio CB: Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk Res 1979:3: 363-370.
118. Allan NC, Richards SM, Shepherd PC: UK Medical Research Council randomized, mul-ticcnter trial of interferon-alpha for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-1397.
119. Hehlmann R. Heimpel H. Hasford J. Kolb HJ.: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994:84:4064-4077.
120. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Treatment of Ph-positive chronic myeloid leukemia with alpha-intcrferon (ROFERON-A): The Italian Cooperative Study Group experience. Leuk Lymph 1993:11 (suppl 1): 153-157.
121. Talpaz M. Kantarjian H. Kurzrock R. Trujilo JM, Guttcrman JU: Interferon-alpha produces sustained cytogenetic response in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med 1991;1 14:532-538.
122. Dowding C. Gordon M, Guo AP, Maison D. Osterholz J, Siczkowski M. Goldman J: Potential mechanisms of action of interferon-alpha in CML. Leuk Lymph 1993: 185-191.
123. Keating A, Guinn BA, Laraya P. Wang XH: a-Interferon downregulatcs transcription of BCR-ABL in colonics arising from Ph+ early hematopoietic progenitors in patients with chronic myeloid leukemia. Blood 1995:86 (suppl l):2096.
124. Talpaz M. Estrov Z. Kantarjian H. Ku S. Foteh A. Kurzrock R: Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia: Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994:94: 1383-1389.
125. Horuk R: Molecular properties of the chemo-kine receptor family. Trends Pharmacol Sci 1994:15:159-165.
126. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B. Moser B, Baggiolini M, Sykes BD: Structurc-activity relationships of chemokines. J Leuk Biol 1995;57:703-7
127. I. Cashman JD. Eaves AC. Wolpe S. Eaves CJ: Regulatory activity of endogenous MIP-1 alpha in long-term cultures of human marrow. ProgrClin Biol Res 1994:389:261-268.
128. Sham RL, Phatak PD. Ihne TP, Abboud CN, Packman CH: Signal pathway regulation of interleukin-8 induced actin polymerization in neutrophils. Blood 1993;82:2546-2551.
129. Adams DH, Harvath L, Bottaro DP, Inter-rante R, Catalano G. Tanaka Y, Strain A, Hubschcr SG. Shaw S: Hepatocyte growth factor and macrophage inflammatory protein 1 beta: Structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc Natl Acad Sci USA 1994;91:7144-7148.
130. Sirard C, Laneuvillc P, Dick JE: Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994:83:1575- 1585.
131. Ihle JN. Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O: Signaling through the hematopoietic cytokine receptors. Ann Rev Immunol 1995; 13:369-398.
132. Hirano T, Matsuda T. Nakajima K: Signal transduction through gpl30 that is shared among the receptors for the interleukin 6 related cvtokine subfamily. Stem Cells 1994; 12:262-277.
133. Levesque JP. Leaveslcy DI. Niutta S, Vadas M. Simmons PJ: Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 1995;181:1805-1815.
134. Kovach NL, Lin N, Yednock T. Harlan JM. Broudv VC: Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines. Blood 1995;85:159-167.
135. Aneskievich BJ, Haimovich B. Boettiger D: Phosphorylation of integrin in differentiating ts-Rous sarcoma virus-infected myogenic cells. Oncogene 1991:6:1381-1390.
136. Johansson MW. Larsson E. Luning B, Pas-quale AB. Ruoslahti E: Altered localization and cytoplasmic domain-binding properties of tyrosinc-phosphorylated ßi integrin. J Cell Bioi 1994:126:1299-1309.
137. Renshaw MW. McWhirter JR. WangJY: The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 1995:15:1286-1293.
138. McWhirter JR. Wang JY: An actin-binding function contributes to transformation by the bcr/abl oncoprotein in Philadelphia chromosome positive human leukemias. EMBO J 1993;12:1533-1546.
139. Bhalia R. Verfaillie CM: Inhibition of BCR/ AB1. expression by anti-sense oligonucleotides normalizes ßl-intcgrin mediated adhesion and regulation of proliferation in chronic myelogenous leukemia. Blood !1995;86(suppl 1): 1740.
140. Greenberg BR, Wilson FD, Woo L. Jenks HM: Cytogenetics of fibroblastic colonies in Phi-positive chronic myelogenous leukemia. Blood 1978:51:1039-1044.
141. Dilly SA, Jagger CJ: Bone marrow stromal cell changes in haematologic malignancies. J Clin Pathol 1990:43:942-946.
142. Caslo-Malaspina H. Gay RE. Jhanwar SC. Hamilton JA, Chiarieri DR, Meyers PA, Gay S, Moore MAS: Characteristics of bone marrow fibroblast colony-forming cells [CFU-F] and their progeny in patients with myeloproliferative disorders. Blood 1982:59:1046- 1054.
143. Kuto F, Nagaoka T, Watanabe Y. Hayashi M, Horasawa Y, Hirasawa Y, Tokuhiro H: Chronic myelocytic leukemia: Ultrastructural histopathology of bone marrow from patients in the chronic phase. Ultrastruct Pathol 1984; 6:307-317.
144. O'Brien S, Kantarjian H. Shtalrid M. Blick M. Beran M, Talpaz M: Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Hematol Pathol 1988:2:25-29.
145. Takahashi M. Keating A, Singer JW: A functional defect in irradiated adherent layers from chronic myelogenous leukemia longterm marrow cultures. Exp Hematol 1985:13: 926-931.
146. Hirata J, Takahira H. Kaneko S, Nishimura J. Nawata H: Bone marrow stromal cells in myeloproliferative disorders. Acta Haematol 1989;82:35-39.
147. Castro-Malaspina H. Laver J, Jhanwar S, Clarkson B. Moore MAS: Studies on the microenvironment in human chronic myelogenous leukemia. Exp Hematol 1984; 12:470- 478.
148. Bathia R. Dewald G. McGlave P. Verfaillie CM: Abnormalities of the bone marrow microenvironment in chronic myelogenous leukemia are related to malignant macrophages. Blood 1995:85:3636-3645